EP3805233
(R) og (S) handhverfur N-(5-(3-hýdroxýpýrrólídín-1-ýl)-2-morfólínóoxasóló[4,5-b]pýridín-6-ýl)-2-(2-metýlpýridín-4-yl)oxasól-karboxamíðs sem irak4 hemlar til meðferðar á krabbameini
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
12.1.2015EP published:
6.3.2024EP application number:
20211096.1
EP translation filed:
8.4.2024Grant published:
15.5.2024EPO information:
European Patent Register
Max expiry date:
11.1.2035Expiry date:
11.1.2027Next due date:
31.1.2027
Title in English:
(R) AND (S) ENANTIOMERS OF N-(5-(3-HYDROXYPYRROLIDIN-1-YL)-2-MORPHOLINOOXAZOLO[4,5-B]PYRIDIN-6-YL)-2-(2-METHYLPYRIDIN-4-YL)OXAZOLE-CARBOXAMIDE AS IRAK4 INHIBITORS FOR THE TREATMENT OF CANCERLanguage of the patent:
English
Timeline
Today
12.1.2015EP application
6.3.2024EP Publication
8.4.2024Translation submitted
15.5.2024Registration published
11.1.2027Expires
Owner
Name:
Aurigene Oncology LimitedAddress:
39-40 KIADB Industrial Area Electronic City Phase II Hosur Road, Bangalore 560100, IN
Inventor
Name:
GUMMADI, Venkateshwar, RaoAddress:
560100 Bangalore, IN
Name:
SAMAJDAR, SusantaAddress:
560078 Bangalore, IN
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
158CH2014Date:
13.1.2014Country:
IN
Number:
3000CH2014Date:
20.6.2014Country:
IN
Classification
Categories:
C07D 498/04, C07D 513/04, C07D 519/00, A61K 31/437, A61P 1/02, A61P 3/00, A61P 5/00, A61P 7/00, A61P 9/00, A61P 11/00, A61P 13/10, A61P 15/00, A61P 17/00, A61P 19/00, A61P 21/00, A61P 25/00, A61P 27/02, A61P 29/00, A61P 31/00, A61P 35/00, A61P 37/02
Annual fees
Number
Paid
Expires
Payer
Number: 11
Paid: 21.2.2025
Expires: 11.1.2026
Payer: Árnason Faktor ehf.
Number: 12
Paid: 7.1.2026
Expires: 11.1.2027
Payer: Árnason Faktor ehf.